Stay updated on Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value of Last Update Posted (Estimated) has been updated to Last Update Posted. This change indicates that the last update posted on the webpage is now the actual date of the update, rather than an estimated date.
    Difference
    0.0%
    Check dated 2024-06-07T15:46:17.000Z thumbnail image
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 04 15 04 12 04 15 -11 7 has recently changed to 06 06 06 05 (Estimated) 06 06 06- 8 on the webpage. This change likely reflects updated data or findings related to the study on Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas, focusing on the drug's effects on certain types of cancer.
    Difference
    0.6%
    Check dated 2024-06-06T14:20:06.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying the need for histologically or cytologically confirmed EBV-positive LPD or EBV-positive NHL, along with other health and treatment history requirements.
    Difference
    42%
    Check dated 2024-05-22T19:50:52.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:32:55.000Z thumbnail image

Stay in the know with updates to Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.